Scarica l'app Stockscreener
10.88
0.27%
-0.03
Dopo l'orario di chiusura:
10.88
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth - AD HOC NEWS
Price to sales forward of Oric Pharmaceuticals, Inc. – DUS:4TZ - TradingView
ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan - Stock Titan
[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Oric Pharmaceuticals stock extends rally with bullish signals after 22 percent weekly surge - Traders Union
ORIC awards new hires 44,400 stock options and 7,200 RSUs - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation - MSN
Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Price to earnings forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Price to book forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Behavioral Patterns of ORIC and Institutional Flows - Stock Traders Daily
ORIC gains as Stifel resumes at buy on upcoming Pfizer readout - MSN
Oric Pharmaceuticals stock trades up as price holds above key supports despite mixed momentum - Traders Union
Oric Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ORIC) - TradingView
ORIC Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Oric Shareholders Approve Equity Plan, Governance Measures - TipRanks
ORIC Pharmaceuticals (ORIC) shareholders back updated equity plan and annual say-on-pay - Stock Titan
Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Oric Pharmaceuticals stock drops 1.62% as Oric Pharmaceuticals marks Juneteenth with diversity message - Traders Union
Oric Pharmaceuticals Inc (ORIC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oric Pharmaceuticals Inc (ORIC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oric Pharmaceuticals Inc (ORIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oric Pharmaceuticals Inc (ORIC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oric Pharmaceuticals Inc (ORIC) Institutional Confidence - TradingKey
Oric Pharmaceuticals Inc (ORIC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oric Pharmaceuticals Inc (ORIC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
(ORIC) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate - Sahm
ORIC Pharmaceuticals (ORIC) Gains on Buy Rating from Stifel Amid Positive Trial Outlook - GuruFocus
ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE) - The Globe and Mail
Stifel initiates Oric Pharmaceuticals stock with buy rating By Investing.com - Investing.com Australia
Buy Rating and $14 Target Set for Oric Pharmaceuticals (ORIC) - GuruFocus
Stifel initiates Oric Pharmaceuticals stock with buy rating - Investing.com
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
ORIC: Phase III prostate cancer trial set to start, with strong safety and efficacy data and robust cash runway - TradingView
Oric Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
ORIC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Oric Pharmaceuticals stock edges up 1.60% as company executives join Goldman Sachs healthcare event, oricpharma - Traders Union
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com South Africa
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):